Taysha Gene Therapies (TSHA) Revenue (2023 - 2025)

Taysha Gene Therapies has disclosed Revenue across 3 years of filings, most recently posting $1.2 million for Q4 2025.

• Revenue for Q4 2025 came in at $1.2 million, down 40.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 million (down 55.73% YoY), and the FY2025 annual result was $5.5 million, down 34.0% from the prior year.
• Revenue came in at $1.2 million for Q4 2025 at Taysha Gene Therapies, down from $2.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $4.7 million in Q3 2023 to a low of $1.1 million in Q2 2024.
• The 3-year median for Revenue is $2.3 million (2025), against an average of $2.7 million.
• Across the five-year window, Revenue slumped 62.33% in 2024 and soared 78.6% in 2025, its largest moves.
• Taysha Gene Therapies' Revenue stood at $3.6 million in 2023, then tumbled by 43.9% to $2.0 million in 2024, then sank by 40.06% to $1.2 million in 2025.
• The last three Revenue figures came in at $1.2 million (Q4 2025), $2.0 million (Q2 2025), and $2.3 million (Q1 2025), per Business Quant data.